Compare TRDA & MSBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | MSBI |
|---|---|---|
| Founded | 2016 | 1881 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.4M | 456.2M |
| IPO Year | 2021 | 2016 |
| Metric | TRDA | MSBI |
|---|---|---|
| Price | $11.70 | $24.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $19.67 |
| AVG Volume (30 Days) | ★ 200.0K | 165.5K |
| Earning Date | 02-26-2026 | 01-22-2026 |
| Dividend Yield | N/A | ★ 5.32% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $61,520,000.00 | ★ $210,718,000.00 |
| Revenue This Year | N/A | $28.14 |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $14.24 |
| 52 Week High | $14.27 | $25.05 |
| Indicator | TRDA | MSBI |
|---|---|---|
| Relative Strength Index (RSI) | 64.79 | 63.71 |
| Support Level | $10.34 | $21.97 |
| Resistance Level | $11.49 | $24.57 |
| Average True Range (ATR) | 0.72 | 0.66 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 83.51 | 56.59 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.